Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

This study has been completed.
Sponsor:
Information provided by:
BeerYaakov Mental Health Center
ClinicalTrials.gov Identifier:
NCT00659919
First received: April 16, 2008
Last updated: June 15, 2008
Last verified: June 2008
  Purpose

Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.


Condition Intervention Phase
Schizophrenia
Drug: Placebo
Drug: Trazodone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by BeerYaakov Mental Health Center:

Primary Outcome Measures:
  • Barnes Akathisia rating scale, Positive and Negative syndrome scale, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms [ Designated as safety issue: Yes ]

Enrollment: 13
Study Start Date: November 2000
Study Completion Date: December 2003
Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
The patients in this arm received placebo
Drug: Placebo
Active Comparator: Trazodone
The patients on this arm received Trazodone for 3 consecutive days
Drug: Trazodone

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with akathisia according to DSM-IV criteria at least mild akathisia.

Exclusion Criteria:

  • Change of pharmacologic regimen 7 days prior to study entry
  • Significant systemic disease
  • The presence of chronic akathisia
  • Patients unable to cooperate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00659919

Locations
Israel
Beer Yaakov MHC
Beer Yaacov, Israel, 70350
Sponsors and Collaborators
BeerYaakov Mental Health Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00659919     History of Changes
Other Study ID Numbers: Trazodone-60CTIL
Study First Received: April 16, 2008
Last Updated: June 15, 2008
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Trazodone
Anti-Anxiety Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 24, 2014